Vimian Group AB (publ) (STO:VIMIAN)

Sweden flag Sweden · Delayed Price · Currency is SEK
25.00
-0.74 (-2.87%)
Mar 3, 2026, 5:29 PM CET
-38.04%
Market Cap 13.23B
Revenue (ttm) 4.60B
Net Income (ttm) 338.73M
Shares Out 529.26M
EPS (ttm) 0.64
PE Ratio 38.80
Forward PE 19.40
Dividend n/a
Ex-Dividend Date n/a
Volume 334,239
Average Volume 424,040
Open 25.84
Previous Close 25.74
Day's Range 24.84 - 25.84
52-Week Range 24.94 - 46.00
Beta 1.42
RSI 34.30
Earnings Date Feb 12, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I... [Read more]

Sector Healthcare
Founded 2020
Employees 1,200
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIMIAN
Full Company Profile

Financial Performance

In 2025, Vimian Group AB's revenue was 425.00 million, an increase of 13.39% compared to the previous year's 374.80 million. Earnings were 31.30 million, an increase of 69.19%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.